Search All News
Source:Medical News Today
Adrian Jacques Ambrose, MD, MPH, FAPA, medical director of the Columbia Psychiatry Faculty Practice Organization, discusses the newest research into the neuroscience of anxiety and depression.
"There's no way that these drugs can meet the fantasized expectations that people have,” David Hellerstein, MD, a professor of clinical psychiatry at Columbia, said in reference to psychedelics.
Columbia Psychiatry is among the principal investigators in biotech Compass Pathways study of more than 200 patients.
Source:New York Times
"The unbridled enthusiasm and commercial momentum generated by psychedelics are excessive and ill advised until we have more sound research," writes Dr. Jeffrey Lieberman.
Source:WHYYJanuary 10, 2020
After a decades-long hiatus, researchers are taking a fresh look at the potential of psychedelics in therapy.
Source:MedscapeOctober 30, 2017
Ecstasy "needs to be looked at in a very careful and rigorously controlled way to accrue evidence showing what it can do and what its potential liability is," says Dr. Jeffrey Lieberman.
Source:New ScientistJanuary 18, 2017
While some people may benefit from sharing their experiences, others risk experiencing more trauma by recalling them, says Dr. Elias Dakwar, Columbia University’s Division on Substance Abuse.